Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).

The Journal of infectious diseases·2026
Same author

Seasonal variations in mold identification in medical microbiology laboratories using MSI-2 application, France (2020-2024).

Medical mycology·2026
Same author

Assessing laboratory capacity for diagnosis of fungal infections in France: A multicentre survey within the SINFONI network.

Medical mycology·2026
Same author

Closing the gap on antifungal resistance.

Nature medicine·2026
Same author

A decade of ocular fungal infections due to Penicillium-like fungi in France (2012-2021).

Medical mycology·2026
Same author

Antifungal susceptibility and molecular characterization of clinical and environmental isolates of <i>Schizophyllum commune</i>.

Journal of clinical microbiology·2026

Related Experiment Video

Updated: Nov 10, 2025

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

19.4K

Special Issue: Antifungal Agents Recently Approved or under Development.

Ana Espinel-Ingroff1, Eric Dannaoui2,3

  • 1Virginia Commonwealth University Medical Center, Richmond, VA 23219, USA.

Journal of Fungi (Basel, Switzerland)
|April 3, 2021
PubMed
Summary

This special issue reviews recently approved and emerging antifungal agents. It covers current knowledge and future perspectives on combating fungal infections.

More Related Videos

Quantifying the Antifungal Activity of Peptides Against Candida albicans
06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

2.6K
Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products
06:47

Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products

Published on: December 5, 2020

6.9K

Related Experiment Videos

Last Updated: Nov 10, 2025

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

19.4K
Quantifying the Antifungal Activity of Peptides Against Candida albicans
06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

2.6K
Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products
06:47

Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products

Published on: December 5, 2020

6.9K

Area of Science:

  • Medical Mycology
  • Pharmacology

Background:

  • Fungal infections pose a significant global health threat, with increasing incidence of drug-resistant strains.
  • The pipeline for new antifungal therapies has been historically limited, necessitating urgent innovation.

Discussion:

  • This special issue consolidates recent advancements in antifungal drug discovery and development.
  • It examines novel mechanisms of action and strategies to overcome antifungal resistance.
  • Key approved agents and promising candidates in clinical trials are highlighted.

Key Insights:

  • Several new antifungal agents with novel mechanisms have recently gained approval or are in late-stage development.
  • Combination therapies and host-directed strategies show potential for improved treatment outcomes.
  • Understanding the evolving landscape of antifungal resistance is crucial for effective therapeutic selection.

Outlook:

  • Future research should focus on broadening the spectrum of activity and improving the safety profiles of antifungal drugs.
  • Development of agents targeting emerging resistant fungal pathogens is a priority.
  • Personalized medicine approaches may optimize antifungal therapy in the future.